Sheet

Please type a plus sign (+) inside this box ->

1

of

+	/	0	•		~	શ્રે
		LASV	n		2002	38
	12	MAY	U	•	2001	į,

I B

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

STAN-202

Under the Paperwork Reduction Act of 1995, no persons all aguired to response a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 09/972.031 **Application Number INFORMATION DISCLOSURE** Filing Date October 4, 2001 STATEMENT BY APPLICANT NAMSARAEV, EUGENI First Named Inventor Group Art Unit 1651 **Examiner Name** Unassigned (use as many sheets as necessary)

Attorney Docket Number

Examiner Initials'	Cite Na. ¹	U.S. Patent Documents Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
NB)		5,015,569	Pontius, B.	05-14-1991	
		5,474,911	Pontius, B.	12-12-1995	
	4	5,132,207	Kohne et al.	07-21-1992	
		5,747,254	Pontius, B.	05-05-1998	
		6,045,996	Cronin et al.	04-04-2000	
		6,040,138	Lockhart et al.	03-21-2000	
		6,043,352	Manoharan et al.	03-28-2000	
DBJ		6,264,825	Blackburn et al.	07-24-2001	
		9			-

					FOREIGN PATENT DOCUM	ENTS		
Examiner	Cite	Fore	ign Patent D	ocuments	Name of Patentee or	Date of Publication	Pages, Columns, Lines,	
Initials'	No.1	Office ³	Number	Kind Code ^s (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
								+
								$\overline{+}$
Examiner	1		./	2./		Date	712502	-

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Plaase type a plus sign (*) molec uns box :	Please type a plus sign (+) inside this	box	_
---	---	-----	---

<u>+</u>	OIPE OF
	MAY 0 1 2002
no persons	are are suired to respond to a co

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

& TRADEMA Complete if Known Substitute for form 1449B/PTO 09/972,031 Application Number INFORMATION DISCLOSURE October 4, 2001 Filing Date First Named Inventor Group Art Unit NAMSARAEV, EUGENI STATEMENT BY APPLICANT 1651 **Examiner Name** (use as many sheets as necessary) Attorney Docket Number STAN-202 2 of Sheet

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
DA)		Tenberge, et al., "Nonradioactive in situ hybridization for detection of hydrophobin mRNA in the phytopathogenic fungus Claviceps purpurea during infection of rye", European J. of Cell Biology 75: 265-272 (March 19987).	
		Hsu, et al., "Genotyping Single-Nucleotide Polymorphisms by the Invader Assay with Dual-Color Fluorescence Polarization Detection", Clinical Chemistry 47:8 1373-1377 (2001).	
		Ambion Catalog Northern & Southern Analysis pages 58-59 (2001).	
		Ambion Catalog Nuclease Protection Assays pages 72-73 (2001).	
		Nedbal, et al., "The Association of Complementary Ribnucleic Acids can be Strongly Increased without Lowering Arrhenius Activation Energies or Significantly Altering Structures", Biochemistry 36: 13552-13557 (1997).	
		Brenner, et al., "In Vitro Cloning of Complex Mixtures of DNA on Microbeads: Physical Separation of Differentially Expressed cDNAs", PNAs Vol 97(4) 1665-1670 (February 15, 2000).	
		Pontius, B., "Close encounters why unstructured, polymeric domains can increase rates of specific macromolecular association", Trends in Biochemical Sciences Volume 18: 181-186 (May 1993).	
		Pontius, et al., "Renaturation of Complementary DNA Strands mediated by Purified mammalian Heterogenous Nuclear Ribonucleoprotein A1 protein: Implications for a Mechanism for Rapid Molecular Assembly", Proc. Natl Acad Sci. Vol. 87: 8403-8407 (November 1990).	
		Pontius, et al., "Rapid Renaturation of Complementary DNA Strands mediated by Catonic detergents: A role for High-Probability Binding Domains in Enhancing the Kinectics of Molecular Assembly Processes", Proc. Natl Acad Sci. Vol. 88: 8237-8241 (September 1991).	
		Sambrook, J., Molecular Cloning, A Laboratory Manual, Chapter 6: Preparation and Analysis of Eukaryotic Genomic DNA, Volume 1: Information Panels 6.61-6.62.	
William Control		Scheitzer, et al., "Combining Nucleic Acid Amplification and Detection", Current Opinion in Biotechnology 12: 21-27 (2001).	
23		Shi, et al., "Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation Detection and Genotyping Technologies", Clinical Chemistry 47:2 164-172 (2001).	

	1		the state of the s
Examiner Diago M		Date Considered	7/25/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.